It is of note that 49 cases of PTDM from the total number of 72 cases during 1 year were developed during the first 3 months post-transplantation.
immediate renal function and more acute rejection. Graft survival was lower although the difference was not significant (1 year: 85 vs 97.5%; 5 years: 74.4 vs 91%; log-rank P = 0.058). There was no difference in patient survival rates. Eight patients in each group presented hepatitis C (HCV) infection. Coinfected patients were compared with HIV+/HCV− and HIV−/HCV+ recipients. Coinfected patients presented more time on dialysis, greater duration of delayed graft function and lower graft survival (HIV+/
Introduction
Positive results from a considerable number of studies regarding the outcome of human immunodeficiency virus (HIV)-infected transplant patients during the high activity antiretroviral therapy (HAART) era have been published [1] [2] [3] [4] [5] [6] [7] [8] [9] . A number of centres in the USA are participating in a National Institutes of Health-supported multicentre prospective trial developed to assess the safety and efficacy of transplantation in HIV-positive patients. Initial results have been presented over the last few months [8, 10] . Nonetheless, there continue to be many controversial issues. Long-term outcome data are scarce, and the possible impact of coinfection by the hepatitis C virus (HCV) is not known. There is little published experience on renal transplantation in Europe [11] [12] [13] . In some European countries, such as Spain, HIV-positive patients present different characteristics which could potentially influence post-transplant outcome [11] [12] [13] [14] .
In 2005, we conducted an initial study in Spain on HIVpositive patients in the HAART era. Since then, the number of kidney transplants and centres performing them has been gradually increasing. The current study is an extension of our previous investigation [11] . Its main objective is to perform a more detailed, longer-term analysis of this population and the comparison with a HIV-negative control group.
Materials and methods
This is an observational, multicentre, retrospective case-control study of HIV-infected patients who received a kidney graft in our country in the HAART era from 2001 to March 2009. Two HIV-negative matched controls were chosen, both transplanted patients, as close as possible in time to the study subjects, at the same hospital and in accordance with the following criteria: similar kidney transplant number, donor type, pre-transplant peak panel-reactive antibodies (PRA), recipient age (±10 years) and donor age (±10 years). If a centre attended to more than one HIV-negative recipient matching those characteristics, we made an additional check with the following criteria in order of importance: similar HCV/HBV recipient serostatus, initial immunosuppression, time on dialysis (±5 years), donor sex and recipient sex. The study was conducted in accordance with international ethical recommendations (Helsinki Declaration) and the Spanish legal regulations. Approval was granted by the ethics committee of the Puerta del Mar Hospital.
The selection of HIV-positive patients for transplantation was conducted following American/Spanish guidelines recommendations [15, 16] . In some centres, grafts from HCV-positive donors were accepted but only for implantation to other HCV-positive recipients. Initial immunosuppression and rejection treatments were indicated following routine practice of each centre. Protocols for prophylaxis of opportunistic infections were similar to HIV-negative patients, except for the prophylaxis against Pneumocystis carinii, which was systematically conducted for HIV-positive patients in many centres.
Variables regarding recipients, donors and kidney transplant outcome were collected. At three months and then on an annual basis, the following parameters were recorded: serum creatinine, glomerular filtration rate, proteinuria and doses/levels of immunosuppressive agents.
Immediate renal function was considered when graft function was sufficient to obviate the need for dialysis during the first week posttransplantation. Delayed graft function (DGF) was defined as the need for post-transplant dialysis (in absence of other causes) with recovery of renal function in the following days. Primary nonfunction was defined as the permanent absence of renal function immediately following transplantation. The diagnosis of rejection was defined according to clinical and histological data (Banff 97 classification).
Statistical analysis
The small sample size was taken into consideration when conclusions were drawn. In addition, based on the sample size needed in order to apply the chi-square test for the comparative analysis of categorical variables, the Fisher's exact test was used when required. Continuous variables were compared using the Kruskal-Wallis or Student's t-tests. Results were expressed as mean ± standard deviation for continuous variables and as frequency for categorical variables. Survival was calculated using the Kaplan-Meier method and groups were compared using the logrank test.
P-values of <0.05 were considered statistically significant. Statistical analysis was done using the SAS v.9.1.3 software.
Results
Over the study period, 23 HIV-infected patients received kidney transplants in 11 Spanish hospitals. Finally, 10 centres with a total of 20 HIV-positive patients participated in the study, together with a matched cohort of 40 HIV-negative recipients. The mean follow-up for all patients was 39.98 ± 36.51 months. All patients were followed up for at least 3 months.
Donor and recipient characteristics are presented in Table 1 . All patients had PRA <25% and received a first renal graft. The prevalence of pre-transplant hypertension and diabetes was similar in both groups. The mean time on dialysis was over twice as long in HIV-positive patients. They presented a significantly higher incidence of pretransplant mycobacterial infections. One HIV-negative patient who received a transplant from a live donor was selected as a control as no other suitable control could be found at that centre.
The main post-transplant complications are shown in Table 2 . HIV-infected recipients presented significantly lower incidence of immediate renal function. The rejection rate was higher, with two patients presenting antibodymediated acute rejection. Serum creatinine levels were constantly higher in HIV-positive recipients, although this difference was not significant. Two patients, one from each group, developed serious neoplastic complications (poorly differentiated invasive breast carcinoma and high-grade Bcell lymphoma).
Specific variables in HIV-infected patients are presented in Table 3 . HIV-associated nephropathy (HIVAN) was not identified in any clinical/histological diagnosis. Only two patients remained without HAART after transplantation because they maintained an adequate immunological and virological control.
Three patients had detectable viral load at the time of surgery (415-1600 copies/mL). Viral load was undetectable in two of these patients after post-transplant initiation of HAART. The third patient presented variable viral load levels, always below 40 000 copies/mL, without HAART support. Another patient with pre-transplant-negative viral load developed low-level post-transplant positive viraemia. patient had a similar follow-up. The deceased patient had viraemia always at low levels, with CD4 counts >500 cells/ mL. No clinically relevant complications were observed and the patient did not receive HAART. Eighty months after transplantation, he developed a non-Hodgkin's B-cell gastrointestinal lymphoma. Immunophenotyping and gene findings excluded Burkitt's lymphoma. The patient was treated with rituximab and CHOP chemotherapy, and HAART was initiated. In the following weeks, the patient suffered numerous complications and died 4 months after diagnosis. Death-censored graft survival (DCGS) was 85% in the first year and 74.4% in the third and fifth years in HIVpositive patients, and 97.5% in the first and third years and 91% in the fifth year in HIV-negative recipients ( Figure 1A) .
Outcome of HCV-infected patients
Comparative analysis of all variables included in the studio both for HIV+/HCV+ (n = 8) and HIV+/HCV− (n = 12) patients was performed. In coinfected recipients, the mean times from HIV infection (12.87 ± 1.47 vs 7.49 ± 5 years) and pre-transplant dialysis duration (8.38 ± 6.21 vs 5.18 ± 5.02 years) were greater, although the difference was not significant. Risk factors for HIV were different: parental drug use was predominant in coinfected patients (seven patients, 87.5%) and sexual transmission in the non-coinfected (eight patients, 66.7%). The rejection rate was similar, and 50% of the patients from both groups developed DGF. However, among coinfected patients, DGF duration was far greater than that observed in those with HIV +/HCV − (16.25 ± 8.42 vs 4 ± 1.67 days, P = 0.0083). The remaining variables were similar in both groups. DCGS was significantly worse in coinfected patients ( Figure 1B) . We also compared the outcomes of HIV+/HCV+ and HIV −/HCV+ (n = 8) patients. The majority of patients were HCV genotype 1 (four HIV+/HCV+, seven HIV−/ HCV+ patients). Although differences were not statistically significant, pre-transplant dialysis time (8.38 ± 6.21 vs 4.25 ± 4.06 years) was also higher in the coinfected recipients. We did not observe any significant differences in the remaining variables. DCGS was also significantly lower among coinfected patients compared to HIV −/ HCV+ recipients ( Figure 1C) .
When comparing HIV-positive patients with HIVnegative patients, excluding patients infected with HCV from both groups (HIV+/HCV−, n = 12; HIV−/HCV−, n = 32), no difference in graft survival was observed ( Figure 1D ).
Discussion
In Spain, HIV-infected patients in dialysis or transplant patients present some different epidemiological characteristics compared to American recipients [11, 14] . Nearly all of our patients are Caucasian as opposed to the predominantly Afro-American subjects in the USA, and so far all of them have received transplants from deceased donors. With regard to ethnic differences, HIVAN is a frequent cause of chronic kidney disease in an American population, whereas in Spain the main renal disease has been glomerulonephritis. Among our patients, parental drug abuse is a very frequent risk factor for HIV infection and, consequently, coinfection with HCV is highly prevalent. These epidemiological differences in the general transplant population may affect graft and patient survival [17] [18] [19] [20] . Despite this, in many aspects, the results have agreed. Graft survival rates are similar to those reported in previous American studies [4, 5, 8, 10, 21] . In a recent analysis of United Network for Organ Sharing database, DCGS in HIV-positive recipients was lower than in HIV-negative subjects when patients received grafts from older donors or when they developed DGF. Conversely, no differences were observed with younger donors or in absence of DGF [22] . In our experience, when another recognized posttransplant risk factor was excluded (i.e. HCV infection), results for both groups have been similar. Prolonged time on dialysis, higher risk of pharmacologic nephrotoxicity or the possible effect of HIV infection on either HCV infec- Fig. 1 . DCGS: Death-censored graft survival. (A) DCGS in HIV-positive (at-risk patients first year, n = 16; third year, n = 13) and HIV-negative recipients (at-risk patients first year, n = 35; third year, n = 21) (log-rank P = 0.0586). (B) DCGS in HIV+HCV+ (at-risk patients first year, n = 5; third year, n = 5) and HIV+HCV− recipients (at-risk patients first year, n = 10; third year, n = 6) (log-rank P = 0.0091). (C) DCGS in HIV+ HCV+ (at-risk patients first year, n = 5; third year, n = 5) and HIV−HCV+ recipients (at-risk patients first year, n = 7; third year, n = 6) (log-rank P = 0.0206). (D) DCGS in HIV+HCV− (at-risk patients first year, n = 10; third year, n = 6) and HIV−HCV− recipients (at-risk patients first year, n = 27; third year, n = 15) (log-rank P = 0.3901).
tion or on the development of rejection could, among other factors, explain this increased susceptibility.
Similar to earlier reports, we have observed a worse renal function in our patients [5, 6, 8] . This cannot be attributed to the use of marginal kidneys, as it happens in some series, since the characteristics of our donors are similar in both groups. Several factors are probably involved, such as antiretroviral-related nephrotoxicity or increased incidence of rejection. Drug interaction between tacrolimus and protease inhibitors leads to extremely high blood levels of tacrolimus. In order to maintain adequate levels, it is necessary to increase the dosing interval, even more than five times [3, 23] . In our study, trough immunosuppressive concentrations were maintained within appropriate therapeutic ranges, similar to those of HIV-negative patients (data no shown). Nonetheless, this strategy could be insufficient to prevent the nephrotoxicity since, although blood trough levels may be appropriate, the renal graft is exposed to high concentrations of tacrolimus during prolonged periods. The development of DGF is another factor of known influence on the graft function [24, 25] . Fifty percent of our HIV-positive patients developed this complication. Interestingly, this observation agrees with other studies [8, 22] . This could also be in part explained by the high risk of drug-associated nephrotoxicity that these patients have.
The general population of HCV-positive kidney recipients shows an increased risk of graft loss in the short and long-term [19] . In HIV-positive patients, the influence of the HCV infection on the outcome of liver transplants has been thoroughly analysed, and the results are less favourable than those for HCV or HIV-monoinfected liver transplant recipients [26] . As yet there are no published studies comparing the outcome after kidney transplantation. In our experience, the outcome of coinfected patients has been worse. Our coinfected population is especially complex. The time on dialysis and the duration of HIV infection are longer and there is a high prevalence of drug addiction backgrounds. After transplantation, the rates of rejection and DGF were similar, but our attention was drawn to the prolonged duration of DGF. This could be because, as we know, patients with liver disease are prone to have elevated tacrolimus levels, which may delay the recovery of renal function. All these pre-and post-transplant factors could explain this worse outcome. However, and although up to now, the results have been less favourable, the number of cases is very limited and consequently no conclusions should be drawn. Based on our experience, we should underline that they are a subgroup of high-risk patients-probably higher than monoinfected-HCV recipients-who must be thoroughly evaluated before surgery and closely followed up after kidney transplantation.
The main limitations of our study are the small number of cases; therefore, the power of the statistical analysis is limited and findings should be interpreted with caution. However, our aim was to perform a detailed analysis of an epidemiologically different population compared to that included in other recent reports. In addition, HIV-infected patients constitute an extremely complex population of recipients receiving a first transplant, so it is difficult to find similar HIV-negative controls. Although we have been unable to obtain matched controls for some variables, both groups could be compared attending to variables of such importance for survival as age, donor characteristics and immunosuppressive treatment, among others. Spain is a country with a low prevalence of HIV infection in dialysis patients, a fact which may perhaps explain the low number of HIV-positive recipients [14] . However, the prolonged time on dialysis may also reflect a delay in the indication of transplantation in these patients that may unnecessarily increase the morbidity and mortality rates [1, 27] .
In conclusion, the observed results for our country agree with those reported in American studies. DCGS was similar to that of HIV-negative recipients when we performed subgroup analyses excluding some risk factors. We observed that patients with HIV-HCV coinfection form the group at higher risk after kidney transplantation. Although in the majority of cases the HIV infection was maintained under control, one patient died after developing lymphoproliferative disease. We consider it advisable to commence HAART immediately after transplantation even in previously untreated patients because they maintained an adequate control of HIV infection. These aspects along with the higher rejection rate and the management and outcome of HIV-HCV coinfection should continue to be the main focus of research in current and future studies.
